175 related articles for article (PubMed ID: 37302750)
21. Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer.
Foldi J; Mougalian S; Silber A; Lannin D; Killelea B; Chagpar A; Horowitz N; Frederick C; Rispoli L; Burrello T; Abu-Khalaf M; Sabbath K; Sanft T; Brandt DS; Hofstatter EW; Hatzis C; DiGiovanna MP; Pusztai L
Breast Cancer Res Treat; 2018 Jun; 169(2):333-340. PubMed ID: 29396664
[TBL] [Abstract][Full Text] [Related]
22. Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70).
Hanusch C; Schneeweiss A; Loibl S; Untch M; Paepke S; Kümmel S; Jackisch C; Huober J; Hilfrich J; Gerber B; Eidtmann H; Denkert C; Costa S; Blohmer JU; Engels K; Burchardi N; von Minckwitz G
Clin Cancer Res; 2015 Jul; 21(13):2924-31. PubMed ID: 25825476
[TBL] [Abstract][Full Text] [Related]
23. Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.
Huober J; Holmes E; Baselga J; de Azambuja E; Untch M; Fumagalli D; Sarp S; Lang I; Smith I; Boyle F; Xu B; Lecocq C; Wildiers H; Jouannaud C; Hackman J; Dasappa L; Ciruelos E; Toral Pena JC; Adamchuk H; Hickish T; de la Pena L; Jackisch C; Gelber RD; Piccart-Gebhart M; Di Cosimo S
Eur J Cancer; 2019 Sep; 118():169-177. PubMed ID: 31377477
[TBL] [Abstract][Full Text] [Related]
24. Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer.
Chen HL; Chen Q; Deng YC
Medicine (Baltimore); 2021 Nov; 100(44):e27632. PubMed ID: 34871229
[TBL] [Abstract][Full Text] [Related]
25. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
Loibl S; von Minckwitz G; Schneeweiss A; Paepke S; Lehmann A; Rezai M; Zahm DM; Sinn P; Khandan F; Eidtmann H; Dohnal K; Heinrichs C; Huober J; Pfitzner B; Fasching PA; Andre F; Lindner JL; Sotiriou C; Dykgers A; Guo S; Gade S; Nekljudova V; Loi S; Untch M; Denkert C
J Clin Oncol; 2014 Oct; 32(29):3212-20. PubMed ID: 25199759
[TBL] [Abstract][Full Text] [Related]
26. Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial.
Conte B; Montemurro F; Levaggi A; Blondeaux E; Molinelli C; Cardinali B; Poggio F; Buzzatti G; Bighin C; Lambertini M; Del Mastro L
Tumori; 2023 Feb; 109(1):71-78. PubMed ID: 34989265
[TBL] [Abstract][Full Text] [Related]
27. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.
Loibl S; Jackisch C; Schneeweiss A; Schmatloch S; Aktas B; Denkert C; Wiebringhaus H; Kümmel S; Warm M; Paepke S; Just M; Hanusch C; Hackmann J; Blohmer JU; Clemens M; Dan Costa S; Gerber B; Engels K; Nekljudova V; von Minckwitz G; Untch M;
Ann Oncol; 2017 Mar; 28(3):497-504. PubMed ID: 27831502
[TBL] [Abstract][Full Text] [Related]
28. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.
Swain SM; Ewer MS; Viale G; Delaloge S; Ferrero JM; Verrill M; Colomer R; Vieira C; Werner TL; Douthwaite H; Bradley D; Waldron-Lynch M; Kiermaier A; Eng-Wong J; Dang C;
Ann Oncol; 2018 Mar; 29(3):646-653. PubMed ID: 29253081
[TBL] [Abstract][Full Text] [Related]
29. Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).
Untch M; von Minckwitz G; Gerber B; Schem C; Rezai M; Fasching PA; Tesch H; Eggemann H; Hanusch C; Huober J; Solbach C; Jackisch C; Kunz G; Blohmer JU; Hauschild M; Fehm T; Nekljudova V; Loibl S;
J Clin Oncol; 2018 May; 36(13):1308-1316. PubMed ID: 29543566
[TBL] [Abstract][Full Text] [Related]
30. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
; Yee D; DeMichele AM; Yau C; Isaacs C; Symmans WF; Albain KS; Chen YY; Krings G; Wei S; Harada S; Datnow B; Fadare O; Klein M; Pambuccian S; Chen B; Adamson K; Sams S; Mhawech-Fauceglia P; Magliocco A; Feldman M; Rendi M; Sattar H; Zeck J; Ocal IT; Tawfik O; LeBeau LG; Sahoo S; Vinh T; Chien AJ; Forero-Torres A; Stringer-Reasor E; Wallace AM; Pusztai L; Boughey JC; Ellis ED; Elias AD; Lu J; Lang JE; Han HS; Clark AS; Nanda R; Northfelt DW; Khan QJ; Viscusi RK; Euhus DM; Edmiston KK; Chui SY; Kemmer K; Park JW; Liu MC; Olopade O; Leyland-Jones B; Tripathy D; Moulder SL; Rugo HS; Schwab R; Lo S; Helsten T; Beckwith H; Haugen P; Hylton NM; Van't Veer LJ; Perlmutter J; Melisko ME; Wilson A; Peterson G; Asare AL; Buxton MB; Paoloni M; Clennell JL; Hirst GL; Singhrao R; Steeg K; Matthews JB; Asare SM; Sanil A; Berry SM; Esserman LJ; Berry DA
JAMA Oncol; 2020 Sep; 6(9):1355-1362. PubMed ID: 32701140
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study).
Dowling GP; Toomey S; Bredin P; Parker I; Mulroe E; Marron J; McLoughlin O; Teiserskiene A; Power C; O'Shea AM; Greally M; Morris PG; Duke D; Hill ADK; Hennessy BT
BMC Cancer; 2024 Jan; 24(1):91. PubMed ID: 38233810
[TBL] [Abstract][Full Text] [Related]
32. PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
Loibl S; Majewski I; Guarneri V; Nekljudova V; Holmes E; Bria E; Denkert C; Schem C; Sotiriou C; Loi S; Untch M; Conte P; Bernards R; Piccart M; von Minckwitz G; Baselga J
Ann Oncol; 2016 Aug; 27(8):1519-25. PubMed ID: 27177864
[TBL] [Abstract][Full Text] [Related]
33. A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
Patel TA; Ensor JE; Creamer SL; Boone T; Rodriguez AA; Niravath PA; Darcourt JG; Meisel JL; Li X; Zhao J; Kuhn JG; Rosato RR; Qian W; Belcheva A; Schwartz MR; Kaklamani VG; Chang JC
Breast Cancer Res; 2019 Sep; 21(1):100. PubMed ID: 31477168
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant Therapy for HER2-positive Breast Cancer.
Wuerstlein R; Harbeck N
Rev Recent Clin Trials; 2017; 12(2):81-92. PubMed ID: 28164759
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada.
Attard CL; Pepper AN; Brown ST; Thompson MF; Thuresson PO; Yunger S; Dent S; Paterson AH; Wells GA
J Med Econ; 2015 Mar; 18(3):173-88. PubMed ID: 25347449
[TBL] [Abstract][Full Text] [Related]
36. BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer.
Liefaard MC; van der Voort A; van Ramshorst MS; Sanders J; Vonk S; Horlings HM; Siesling S; de Munck L; van Leeuwen AE; Kleijn M; Mittempergher L; Kuilman MM; Glas AM; Wesseling J; Lips EH; Sonke GS
Breast Cancer Res; 2023 Jun; 25(1):71. PubMed ID: 37337299
[TBL] [Abstract][Full Text] [Related]
37. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J
Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998
[TBL] [Abstract][Full Text] [Related]
38. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
[TBL] [Abstract][Full Text] [Related]
39. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
Bianchini G; Kiermaier A; Bianchi GV; Im YH; Pienkowski T; Liu MC; Tseng LM; Dowsett M; Zabaglo L; Kirk S; Szado T; Eng-Wong J; Amler LC; Valagussa P; Gianni L
Breast Cancer Res; 2017 Feb; 19(1):16. PubMed ID: 28183321
[TBL] [Abstract][Full Text] [Related]
40. A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.
Masuda N; Ohtani S; Takano T; Inoue K; Suzuki E; Nakamura R; Bando H; Ito Y; Ishida K; Yamanaka T; Kuroi K; Yasojima H; Kasai H; Takasuka T; Sakurai T; Kataoka TR; Morita S; Ohno S; Toi M
Breast Cancer Res Treat; 2020 Feb; 180(1):135-146. PubMed ID: 31953696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
